Aramis Biosciences is a clinical-stage immuno‑ophthalmology biopharmaceutical company committed to the development of disease‑modifying therapy for ocular surface disease

Aramis Biosciences was founded in 2018 following more than a decade of research at The Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, where the role of a certain subset of pro-inflammatory T helper cells were found to be central to the immunopathogenesis of dry eye disease.

Since then, Aramis Biosciences has assembled a team of accomplished pharmaceutical executives and world-renowned experts in the fields of ophthalmology and immunology, all committed to Aramis Biosciences’ mission to revolutionize the standard of care in ocular surface disease. Aramis Biosciences is further supported by its strategic partners, institutional investors and academic collaborators.